These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35743091)

  • 21. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
    Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
    Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
    Puig L
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.
    Boehncke WH; Boehncke S; Tobin AM; Kirby B
    Exp Dermatol; 2011 Apr; 20(4):303-7. PubMed ID: 21410760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing cardiovascular risk in patients with chronic inflammatory diseases.
    Haraoui B; Liu PP; Papp KA
    Clin Rheumatol; 2012 Apr; 31(4):585-94. PubMed ID: 22246418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis strikes back! Epicardial adipose tissue: another contributor to the higher cardiovascular risk in psoriasis.
    Raposo I; Torres T
    Rev Port Cardiol; 2015 Oct; 34(10):613-6. PubMed ID: 26417656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis.
    Lockshin B; Balagula Y; Merola JF
    J Am Acad Dermatol; 2018 Aug; 79(2):345-352. PubMed ID: 29477740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiometabolic Disorders in Psoriatic Disease.
    Sobchak C; Eder L
    Curr Rheumatol Rep; 2017 Aug; 19(10):63. PubMed ID: 28844116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psoriasis as a systemic disease.
    Grozdev I; Korman N; Tsankov N
    Clin Dermatol; 2014; 32(3):343-50. PubMed ID: 24767182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ischemic cardiovascular involvement in psoriasis: a systematic review.
    Mosca S; Gargiulo P; Balato N; Di Costanzo L; Parente A; Paolillo S; Ayala F; Trimarco B; Crea F; Perrone-Filardi P
    Int J Cardiol; 2015 Jan; 178():191-9. PubMed ID: 25464252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel anti-inflammatory therapies to reduce cardiovascular burden of psoriasis.
    Piros ÉA; Szilveszter B; Vattay B; Maurovich-Horvat P; Szalai K; Dósa E; Merkely B; Holló P
    Dermatol Ther; 2021 Jan; 34(1):e14721. PubMed ID: 33373079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comorbidities in patients with psoriasis.
    Gottlieb AB; Dann F
    Am J Med; 2009 Dec; 122(12):1150.e1-9. PubMed ID: 19958894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk and psoriasis: the role of biologic therapy.
    Puig L
    Actas Dermosifiliogr; 2012 Dec; 103(10):853-62. PubMed ID: 23157913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.
    Garshick MS; Ward NL; Krueger JG; Berger JS
    J Am Coll Cardiol; 2021 Apr; 77(13):1670-1680. PubMed ID: 33795041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences.
    Boehncke WH; Boehncke S
    G Ital Dermatol Venereol; 2008 Oct; 143(5):307-13. PubMed ID: 18833072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.
    Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
    J Dermatol; 2017 Apr; 44(4):363-369. PubMed ID: 27774694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Psoriasis, a systemic disease?].
    Puig-Sanz L
    Actas Dermosifiliogr; 2007; 98(6):396-402. PubMed ID: 17663929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study.
    Montaudié H; Albert-Sabonnadière C; Acquacalda E; Fontas E; Danré A; Roux C; Ortonne JP; Lacour JP; Euller-Ziegler L; Passeron T
    J Eur Acad Dermatol Venereol; 2014 Sep; 28(9):1186-91. PubMed ID: 23981008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis comorbidities.
    Guenther L; Gulliver W
    J Cutan Med Surg; 2009; 13 Suppl 2():S77-87. PubMed ID: 19799830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An atypical presentation of atherosclerosis in psoriasis: "Porcelain aorta"].
    Magis Q; Carsuzaa F; Flavian A; Darmon A; Grob JJ; Richard MA
    Ann Dermatol Venereol; 2015; 142(6-7):421-4. PubMed ID: 25888457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular risk in systemic inflammatory diseases].
    Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
    G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.